Anthem Biosciences Ltd (ANTHEM)
🎯 Key Takeaways
- Anthem Biosciences Ltd is transitioning from a high-growth phase to a disciplined, margin-focused turnaround, leveraging strong cash reserves and operational efficiency to navigate revenue volatility. Despite a 22.
- Revenue declined 31.5% QoQ to ₹418 in Q1FY27.
- ⚠️ Revenue volatility due to customer delivery timing shifts poses near-term top-line uncertainty.
📖 The Story
Anthem Biosciences Ltd is transitioning from a high-growth phase to a disciplined, margin-focused turnaround, leveraging strong cash reserves and operational efficiency to navigate revenue volatility. Despite a 22.6% YoY revenue decline in Q1FY27 due to delivery timing shifts, the company is demonstrating resilience through robust EBITDA and PAT margins, supported by cost optimization and yield improvements. Management is prioritizing long-term structural profitability over short-term top-line expansion, signaling a strategic pivot toward sustainable value creation.
📰 What's Happening
In Q1FY27, Anthem reported consolidated revenue of ₹4,182 crores, down 22.6% YoY, with EBITDA margin expanding to 39.6% and PAT margin at 27.1%. CRDMO revenue stood at ₹3,408 crores, while specialty ingredients contributed ₹774 crores. The company highlighted timing shifts in customer deliveries as a factor in revenue decline but emphasized sustained demand and margin discipline. Management expects revenue growth to resume in H2FY27 driven by cost efficiencies and yield optimization. The Board approved unaudited financials and ESOPS share issuance, while the 45th AGM passed all resolutions, including dividend approval and auditor reappointment, reflecting strong governance confidence.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 550 | 423 | 611 | 418 |
| Operating Profit | 184 | 123 | 228 | 121 |
| OPM % | 33.5% | 29.0% | 37.3% | 28.8% |
| Net Profit | 173 | 93 | 190 | 120 |
| EPS | ₹3.09 | ₹1.65 | ₹3.38 | ₹2.13 |
Quarterly financials show a clear trend of margin expansion despite revenue softness: OPM held steady at ~29% in Dec 2025 and Jun 2026, with EBITDA margin rising 153 bps YoY to 39.6% in Q1FY27. PAT margin improved from prior quarters, and net cash position strengthened to ₹17,197 crores. Revenue dipped in Q1FY27 but remains volatile across prior quarters (₹423–₹611 crores), indicating delivery-driven fluctuations. However, profitability has held firm, with PAT margins improving and EBITDA consistently above 38%. This suggests management is successfully decoupling profitability from top-line pressure through operational levers.
🔮 Management Outlook & What's Next
Management expects sustained revenue growth aligned with historical performance and improved margins through cost efficiencies and yield optimization in H2FY27. While no specific growth targets were provided, the commentary underscores a focus on margin discipline, operational resilience, and long-term demand stability. Forward-looking statements were included in the earnings release, reinforcing confidence in the company’s ability to navigate cyclical demand while strengthening profitability. The tone remains cautiously optimistic, anchored in structural improvements rather than cyclical recovery.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 112 | 112 | 112 |
| Reserves | 2,298 | 2,640 | 2,930 |
| Borrowings | 110 | 108 | 51 |
| Total Liabilities | 2,808 | 3,284 | 3,429 |
| Fixed Assets | 701 | 766 | 783 |
| Investments | 433 | 545 | 1,007 |
| Total Assets | 2,808 | 3,284 | 3,429 |
The balance sheet reflects a strong capital structure with negligible debt (D/E of 0.02) and growing equity and reserves. Total assets rose to ₹3,429 crores as of March 2026, up from ₹2,808 crores in March 2025, driven by asset growth and retained earnings. Borrowings remain low at ₹108 crores, down from ₹110 crores a year ago, indicating no leverage increase. The company’s cash position is robust, with net cash at ₹17,197 crores, supporting strategic flexibility, including potential M&A or capital returns. The recent ESOPS issuance signals intent to align employee incentives with long-term value creation without diluting financial stability.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +844 |
| Investing | -702 |
| Financing | -40 |
| Net Cash Flow | +103 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 74.7% | 74.7% | 74.7% | 71.4% |
| FII | 1.7% | 1.4% | 1.3% | 2.6% |
| DII | 7.2% | 7.6% | 11.5% | 13.5% |
| Public | 9.6% | 9.6% | 9.4% | 9.4% |
| # Shareholders | 2,17,681 | 1,99,492 | 1,80,220 | 1,73,273 |
Promoter holding remains stable at 71.42% in Q1FY27, with no signs of dilution or sell-down. FII and DII holdings have modestly increased to 2.58% and 13.48% respectively, up from 1.28% and 11.54% in Q4FY26, suggesting growing institutional confidence. The number of public shareholders has slightly declined, but overall shareholder base remains broad. No pledging or significant exits were disclosed. The stable promoter stake and rising institutional interest indicate confidence in the company’s governance and long-term strategy.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.42 L Cr | 36.5 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.48 L Cr | 84.6 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.89 L Cr | 79.4 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.12 L Cr | 24.9 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.10 L Cr | 32.7 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.06 L Cr | 97.3 | 20.8% | 20.6% | 0.45 |
| DRREDDY | 96,906 | 30.0 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 96,402 | 26.2 | 12.8% | 9.8% | 0.20 |
| LUPIN | 95,836 | 16.9 | 27.9% | 24.7% | 0.26 |
| MANKIND | 94,039 | 46.0 | 13.9% | 12.7% | 0.38 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Revenue volatility due to customer delivery timing shifts poses near-term top-line uncertainty. 2. High reliance on CRDMO segment (81% of revenue) makes the company vulnerable to sector-specific demand and pricing pressures. 3. Despite margin resilience, sustained revenue growth is critical — any delay in demand recovery could pressure profitability. 4. Regulatory and compliance risks in the pharmaceutical sector, though mitigated by strong governance, remain inherent in global operations.
📋 Recent Filings
-
🟡 Board Meeting 8 September 2026Anthem Biosciences announced settlement of its upside sharing arrangement with principal shareholders following shareholder approval at the July 22, 2...
-
Announcement 27 July 2026Anthem Biosciences reported Q1 FY27 results showing consolidated revenue of Rs 418 crores, with CRDMO contributing 81.5% and specialty ingredients 18....
-
🟡 Board Meeting 24 July 2026Anthem Biosciences held its 45th AGM on July 22, 2026, approving all 8 resolutions including audited financial statements, dividend declaration, direc...
-
🔴 Financial Results 22 July 2026Anthem Biosciences Limited announced that the audio recording of its earnings call for the quarter ended June 30, 2026, held on July 22, 2026, is now ...
-
🟡 Board Meeting 21 July 2026Anthem Biosciences announced the outcome of its board meeting held on July 21, 2026, where it approved unaudited standalone and consolidated financial...
-
🔴 Financial Results 21 July 2026Anthem Biosciences reported consolidated revenue of ₹4,182 crores for Q1FY27, down 22.6% YoY, with EBITDA at ₹1,755 crores and PAT at ₹1,199 crores. E...
-
🔴 Financial Results 21 July 2026Anthem Biosciences reported consolidated revenue of ₹4,182 Mn for Q1FY27, down 22.6% YoY, with EBITDA at ₹1,755 Mn (39.6% margin) and PAT at ₹1,199 Mn...
-
🔴 Financial Results 21 July 2026Anthem Biosciences reported Q1FY27 consolidated revenue of ₹4,182 Mn, down 22.6% YoY, with EBITDA at ₹1,755 Mn (39.6% margin) and PAT at ₹1,199 Mn (27...
-
Financial Results 2 July 2026Anthem Biosciences clarified that its FY2026 PAT of ₹5,917.92 million matches the XBRL filing, correcting a prior discrepancy, and will promptly revis...
-
🔴 annual report 30 June 2026Anthem Biosciences Limited voluntarily published its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, aligning with SEBI's upc...
🧠 Analyst's Read
Anthem Biosciences is executing a disciplined margin-focused strategy amid temporary revenue headwinds, supported by strong cash flows, low leverage, and institutional confidence. The key watchpoint is the pace of revenue recovery in H2FY27, which will determine whether current profitability improvements can be sustained. Investors should monitor delivery patterns, order intake, and management’s ability to convert margin gains into top-line growth.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-12.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ANTHEM files new disclosures
Track ANTHEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ANTHEM — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd